Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Apyx Medical Corp (APYX)

Apyx Medical Q3 revenue rises 9% to $14.0 million; net loss narrows

Positive Impact 3 of 5 earnings Written later

Apyx Medical reported third-quarter 2026 revenue of $14.0 million, up 9% from $12.9 million a year earlier, led by a 17% rise in Surgical Aesthetics sales. The net loss attributable to stockholders narrowed to $1.8 million, or $0.04 per share, from $2.0 million, or $0.05 per share. The company reaffirmed its full-year 2026 revenue guidance of $59.0 million to $60.0 million and lowered its operating expense target to $41.0 million to $42.5 million.

Key points

  • Q3 2026 total revenue was $14.0 million versus $12.9 million in Q3 2025; OEM revenue fell 42% to about $1.1 million.
  • Net loss attributable to stockholders was $1.8 million ($0.04 per share), compared with $2.0 million ($0.05 per share) a year earlier.
  • Adjusted EBITDA was $0.4 million, compared with a loss of $0.1 million in Q3 2025.
  • FY2026 revenue guidance of $59.0 million to $60.0 million was reaffirmed; operating expense guidance was cut to $41.0 million to $42.5 million from less than $45.0 million.

The filing

CompanyApyx Medical Corp (APYX)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:02 AM ET
Accession number0001437749-26-035079

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.